Acta Pharm. 68 (2018) 457-469

 

full paper

Original research paper

 

Immunomodulatory effects of tigecycline in Balb/c mice

SHADA Y. ELHAYEK, MOHAMMAD A. FARARJEH, AREEJ M. ASSAF, EMAN ABU RISH and YASSER BUSTANJI

bustanji@ju.edu.jo

1 Department of Biopharmaceutics and Clinical Pharmacy
School of Pharmacy, University of Jordan, Amman, Jordan

2 Al-Quds medical labs, AL-Zarqa, Jordan

3 Hamdi Mango Center for Scientific Research, Amman, Jordan

Accepted July 5, 2018

Published online September 10, 2018

 

Tigecycline is a glycylcycline antibiotic approved by the FDA for the treatment of complicated infections. Despite its effectiveness, the FDA announced a warning of increasing mortality associated with its use. There is, however, no clear explanation for this side effect. Previous reports found a possible effect of tigecycline on leukocyte proliferation and proinflammatory cytokine release. We therefore investigated the effect of tigecycline on the immune components and response in Balb/c mice in vivo and in vitro. It was found that tigecycline enhanced lymphocyte proliferation and significantly increased cellular infiltration within the footpad, as based on DTH testing, but reduced the hemagglutination titer. In splenocyte cultures, tigecycline suppressed splenocyte proliferation with IC50 35 mmol L1, significantly increased IL-2 secretion and reduced IL-17 secretion in a dose dependent mode. In conclusion, tigecycline is safe at therapeutic and sub-therapeutic doses, but it could still have an immunomodulatory effect at higher doses. Use of higher doses of tigecycline requires further investigation.

 

Keywords: tigecycline, immunomodulation, Balb/c mice, biochemical effect